Developing Patient-Derived 3D-Bioprinting models of pancreatic cancer

The study on patient-derived 3D-bioprinting models of pancreatic cancer highlights their effectiveness as preclinical tools, as they maintain essential genomic and histological features. These models exhibit drug sensitivity profiles that may correlate with clinical outcomes, suggesting their potential in personalizing treatment strategies and forecasting patient prognoses. However, further validation with larger patient cohorts is necessary to confirm their clinical utility.